Kinfo
Sana Biotechnology Inc. logo

Sana Biotechnology Inc.

SANANASDAQHealthcare·US · USD
$2.41
+0.07 (+2.99%)
Prices as of November 6, 2026 · live

Price

Key statistics

Valuation
Market cap700.50M USD
Enterprise value620.95M USD
Trailing P/E-2.43
Forward P/E-4.22
PEG ratio0.06
Price / sales0.00
Price / book4.53
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-29.16%
Return on equity-152.87%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-174.19M USD
Net income-211.82M USD
Diluted EPS-$0.76
Rev. growth (YoY)0.00%
Balance sheet
Total cash160.49M USD
Total debt80.94M USD
Debt / equity52.37
Current ratio1.38
Book value / share$0.52
Cash flow (TTM)
Operating cash flow-132.24M USD
Levered free cash flow4.13M USD
Shares & price
Shares outstanding299.31M
Float190.89M
Held by institutions77.58%
Beta2.30
50-day MA$2.95
200-day MA$3.36
52-week high$5.49
52-week low$2.22
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-10-0.12-0.13−8.33%2026-07-233.323.52+6.02%2026-05-11-0.15-0.14+6.67%2026-05-040.780.87+11.54%2026-03-03-0.13-0.16−23.08%
About Sana Biotechnology Inc.

Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms designed to address serious diseases with unmet treatment needs, including type 1 diabetes, B cell-mediated autoimmune diseases, oncology, and other immune-related conditions. Its work centers on modifying, replacing, or repairing cells to support next-generation therapeutic approaches, with research and development spanning cell therapy, gene delivery, and immune evasion technologies. Sana Biotechnology operates as a clinical-stage company and does not yet market approved commercial therapies, making its role in the market primarily centered on innovation, pipeline development, and translational research. Headquartered in Seattle, Washington, the company is part of the broader biotechnology sector, where engineered-cell platforms are an important area of active drug development.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Steven D. Harr M.D.
Employees
142
Headquarters
Seattle, WA, United States

Frequently asked questions about Sana Biotechnology Inc.